Cancer News and Research

Latest Cancer News and Research

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy.

29 Oct 2009

Biomoda to launch multisite Phase III clinical trials of CyPath assay

Medical diagnostics company Biomoda, Inc. is taking preliminary steps to launch multisite Phase III clinical trials of its in-vitro diagnostic for early-stage lung cancer, trademarked under the name CyPath®.

29 Oct 2009

Berkeley HeartLab enters into collaborative agreement

Berkeley HeartLab (BHL), a subsidiary of Celera Corporation, announced today that it has entered into collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service recently launched by Geisinger Health System.

29 Oct 2009

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains. Moreover, in Asian countries such as Indonesia, Japan, China, and Thailand, where the H. pylori infection rates are similar, there is a significant difference regarding the outcome of gastric cancer. That fact has been termed the "Asian paradox".

29 Oct 2009

New anti-cancer medications may help in managing cancerous conditions

Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

29 Oct 2009

HD colonoscopy is more sensitive than standard colonoscopy in finding polyps: Study

High-definition (HD) colonoscopy is much more sensitive than standard colonoscopy in finding polyps that could morph into cancer, say researchers at the Mayo Clinic campus in Florida.

29 Oct 2009

Canadians should consider taking Vitamin D during fall and winter months

Changing our clocks on Sunday November 1 is an excellent time to consider taking a daily Vitamin D supplement, says the Canadian Cancer Society.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

NIGMS accelerates induced pluripotent stem cells study with Recovery Act funds

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health, is using $5.4 million of Recovery Act funds to accelerate basic studies of induced pluripotent stem cells. These cells, abbreviated iPS, are reprogrammed from skin or other easily obtained adult cells and appear to be similar to stem cells derived from embryos.

28 Oct 2009

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

The human body contains billions of microorganisms, and microbial cells found in the human gut are estimated to outnumber human cells by ten-to-one in healthy adults. However, little is known about the ways in which these minute life forms influence health and disease.

28 Oct 2009

NeuroVasx cPAX Aneurysm Treatment System: first procedure in Spain performed

NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that the first procedure in Spain utilizing its cPAX Aneurysm Treatment System was performed in Madrid. cPAX received CE Mark earlier this year.

28 Oct 2009

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease.

28 Oct 2009

Philanthropist gifts $10-million to Sunnybrook Foundation

The people of Ontario will have more access than ever to the latest life-saving, minimally invasive cardiovascular treatments thanks to the visionary leadership of one of Canada's foremost philanthropists, Seymour Schulich.

28 Oct 2009

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

28 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. The benefits of this product lies in its composition and, thus, its study, identification and subsequent extraction provides a useful tool which enables making high added-value products, given their high concentration of biologically active compounds.

28 Oct 2009

Nashboro Village Family Dental's initiative for childhood cancer

On Saturday, November 21, 2009 Nashboro Village Family Dental will present our First Annual Super Talent and All-Star Show. Hosted by Lelan Statom, WTVF, NewsChannel 5, this event will benefit Operation Stand Down and one of our patients that is battling chronic childhood cancer.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Cancer News and Research

Latest Cancer News and Research

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

Biomoda to launch multisite Phase III clinical trials of CyPath assay

Berkeley HeartLab enters into collaborative agreement

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

New anti-cancer medications may help in managing cancerous conditions

HD colonoscopy is more sensitive than standard colonoscopy in finding polyps: Study

Canadians should consider taking Vitamin D during fall and winter months

Moores UCSD Cancer Center awarded $20 million for cancer research

NIGMS accelerates induced pluripotent stem cells study with Recovery Act funds

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

NeuroVasx cPAX Aneurysm Treatment System: first procedure in Spain performed

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Philanthropist gifts $10-million to Sunnybrook Foundation

NCI awards UAMS Myeloma Institute $19.5M grant

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Pure Protein develops soluble Class II human leukocyte antigens

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

Nashboro Village Family Dental's initiative for childhood cancer

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in